Meeting the UK demand for COVID19/SARS-CoV-2 vaccines via integrated manufacturing and supply chain optimisation

Lead Research Organisation: Imperial College London
Department Name: Department of Chemical Engineering


With the world's exit strategy from the current Covid-19 pandemic dependent on developing herd immunity through mass vaccination, there is imminent need to develop a roadmap for vaccine rapid manufacture and distribution at unprecedented scale. We seek funding to develop a blueprint for ramping up production, distribution and administration of SARS-CoV-2 vaccines based on a stratified vaccination strategy that starts with front-line personnel all the way to mass vaccination of the general UK population.

To do this, we will combine process modelling with supply-chain optimisation to ensure (a) drug product and final drug substance availability, and (b) that production goes hand-in-hand with immediate availability for progressively larger parts of the population.

Our models will be open-source and publicly available, and they will subsequently be extended to describe European manufacturing capabilities and vaccination campaigns. We are members of both the UCL-Oxford VaxHub and Imperial's Future Vaccine Manufacturing Hub (FVMH) and have had early access to data for the viral vector vaccine developed by the Jenner Institute and the saRNA vaccine developed by the Shattock group. As such,we have already developed manufacturing models and have been working on optimisation and scaling up strategies.

With these two technologies being the global frontrunners in the race to clinical trials (e.g. Moderna in the USA is in Phase I clinical trials, NCT04283461 and Curevac in Germany is aiming to enter clinical trials in early summer 2020), our models will be applicable to any of these vaccines that receive regulatory approval.
Description We have demonstrated what it would take to achieve 500,000 Covid vaccinations daily
Exploitation Route They can be used for other countries
Sectors Pharmaceuticals and Medical Biotechnology

Description They have been used to inform an important DELVE report.
First Year Of Impact 2020
Sector Pharmaceuticals and Medical Biotechnology
Impact Types Policy & public services

Description Production and launch of DELVE report
Geographic Reach National 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
Impact Provided guidance about vaccine manufacturing and roll-out for Covid
Title Vaccine supply chain model 
Description Optimisation model which is able to plan the operations of a national or international vaccine supply chain, particularly in pandemic situations 
Type Of Material Computer model/algorithm 
Year Produced 2022 
Provided To Others? Yes  
Impact The model has been published and used to develop scenarios. 
Description collaboration with GSK vaccines 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution We have provided new concepts in quality by design and supply chain modelling
Collaborator Contribution We have co-developed an approach to quality by design and supply chain modelling
Impact n/a
Start Year 2020